• Lypressin Acetate: Identity, Mechanism, and Evidence

  2026-10-15

  Lypressin acetate, also called Lysine vasopressin acetate, is described by APExBIO as a lysine-containing vasopressin analog and agonist of V1a, V1b, and V2 receptors. The available information supports a documented pharmacological identity and a set of reported bioactivity measurements, but it does not provide an identity-matched research paper, assay methods, comparators, or independent evidence for the proposed SARS-CoV-2 RdRp or pregnancy-safety claims.

• When Context Changes the Meaning of AR Results

  2026-10-15

  EPI-001 research illustrates why the same molecular result can mean different things in prostate cancer models, TNBC cell lines, patient cohorts, and public transcriptomic datasets. The evidence supports a context-dependent association between AR/ARv7 and adverse TNBC features, while the cell-based findings provide mechanistic hypotheses rather than clinical evidence.

• Oleic Acid Evidence in Hepatic Ischemia–Reperfusion

  2026-10-14

  A 2024 mouse and hepatocyte study linked Rehmanniae Radix Praeparata extract with improved hepatic ischemia–reperfusion injury and altered AMPK–mTOR, SCAP–SREBP2, and LXRα-associated lipid readouts. Because the cellular model combined Oleic Acid with palmitic acid and the intervention was a complex botanical extract, the findings support a mechanistic hypothesis about lipid dysregulation rather than an Oleic Acid-specific or clinically established effect.

• Human Sensory Neurons as a Model of HSV-1 Latency

  2026-10-14

  Oh and colleagues developed a human induced-pluripotent-stem-cell-derived sensory-neuron system designed to model HSV-1 latency and reactivation. The study reports several molecular and virological features consistent with latency, including absence of detectable infectious virus, reduced lytic transcription, latency-associated transcript expression, and viral heterochromatin. The model is promising for studying neuron-intrinsic mechanisms, but its in vitro and stem-cell-derived nature limits direct extrapolation to human ganglia, disease, or treatment.

• CXCR4–EGFR Heteromers: What the Data Show

  2026-10-13

  A 2026 Cell Chemical Biology study reports that CXCR4 and EGFR can form ligand-responsive signaling complexes. The evidence supports receptor proximity and altered coupling to intracellular partners, but does not establish a fixed heteromeric architecture, clinical relevance, or any effect of Erlotinib on these complexes.

• Baicalin and Adult Visual Plasticity: Evidence Boundaries

  2026-10-13

  A 2026 mouse study links baicalin with renewed ocular dominance plasticity and visual recovery in an adult amblyopia model. The findings are mechanistically suggestive but remain preclinical, model-specific, and insufficient to establish human efficacy, safety, or relevance to oncology claims.

• DHEA-PCOS Models: What the Evidence Shows

  2026-10-12

  A 2025 rat and theca-cell study links Jiao-tai-wan and coptisine to SIRT1, mitochondrial dynamics, and ovarian steroidogenesis in a DHEA-induced PCOS model. The findings support a mechanistic hypothesis, but they do not establish clinical efficacy, prove pathway exclusivity, or show that DHEA-related effects generalize to neuroprotection or other biological contexts.

• BAPTA and Calcium Signaling in Co-Exposure Toxicity

  2026-10-12

  A 2026 Toxicology study links polystyrene nanoplastic–cadmium co-exposure with intestinal apoptosis in C. elegans and Caco-2 models, implicating an IP3R/Ca2+/STAT3 signaling axis. BAPTA-related calcium chelation reduced reported pathway and apoptosis responses, supporting calcium involvement while not establishing human health effects or exclusive pathway causality.

• STING Agonist-1: Evidence, Mechanisms, and Limits

  2026-10-11

  A source-grounded overview of STING agonist-1 and its relevance to innate immune signaling, B-cell biology, tertiary lymphoid structures, and esophageal squamous cell carcinoma research. The discussion separates supplier claims from findings reported in a 2025 Cancer Gene Therapy study and outlines evidence strength, conceptual applications, and translational limitations.

• How Pollen Interference Shapes Bioaerosol Classification

  2026-10-10

  Zhang et al. show that pollen can distort excitation–emission matrix fluorescence profiles used to classify hazardous biological samples. Their combination of spectral transformation and random-forest classification improved reported accuracy to 89.24%, while also highlighting the dataset and validation limits that affect real-world interpretation.

• Digoxin Beyond Cardiac Glycosides: A Translational View

  2026-10-09

  A source-grounded perspective on Digoxin as a Na+/K+ ATPase pump inhibitor, connecting cardiac contractility modulation with reported cell-context-dependent chikungunya findings while defining evidence boundaries, comparator strategy, and translational priorities.

• Removing Pollen Interference in Bioaerosol Spectra

  2026-10-09

  Zhang et al. examined how pollen fluorescence can confound the classification of hazardous biological substances using excitation–emission matrix spectroscopy. Their central contribution was a feature-transformation and random-forest framework in which fast Fourier transform processing improved the reported classification accuracy to 89.24%, while important limitations remain around validation scope and transferability.

• NF-κB/miR-202-5p/HMGB2 in Septic AKI

  2026-10-08

  Wang and colleagues identify an NF-κB/miR-202-5p/HMGB2 negative feedback loop that limits inflammation and tubular injury in experimental septic acute kidney injury. The findings connect inflammatory transcription, microRNA-mediated repression, and HMGB2-dependent NF-κB activity, while remaining preclinical and model-dependent.

• KX2-391 Dihydrochloride: HBV Research Evidence

  2026-10-08

  KX2-391 dihydrochloride, also called Tirbanibulin dihydrochloride, has peer-reviewed evidence as a research lead for suppressing HBV transcription in cell-based models. The strongest published findings implicate tubulin polymerization rather than Src kinase inhibition, while evidence for oncology, botulinum neurotoxin A, and other applications remains context-dependent or outside the supplied primary study.

• Novobiocin Sodium: Evidence and Research Context

  2026-10-07

  Novobiocin Sodium is an aminocoumarin antibiotic best established as a bacterial DNA gyrase inhibitor, while recent in vitro research suggests activity against Toxoplasma gondii. This overview separates reported findings from broader research hypotheses and explains why the current evidence supports mechanistic investigation rather than clinical or translational conclusions.

8152 records 1/544 page Next 12345 下5页 Last page